VYNE Therapeutics (NASDAQ:VYNE) Issues Earnings Results

VYNE Therapeutics (NASDAQ:VYNE) posted its quarterly earnings data on Friday. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.10, FiscalAI reports. VYNE Therapeutics had a negative return on equity of 74.86% and a negative net margin of 4,646.14%.The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.20 million.

VYNE Therapeutics Stock Performance

Shares of VYNE Therapeutics stock traded down $0.00 on Friday, hitting $0.67. 106,397 shares of the company’s stock were exchanged, compared to its average volume of 292,626. The company has a 50-day simple moving average of $0.62 and a 200-day simple moving average of $0.54. VYNE Therapeutics has a 1 year low of $0.28 and a 1 year high of $1.96. The stock has a market capitalization of $22.32 million, a PE ratio of -0.86 and a beta of 2.00.

Institutional Investors Weigh In On VYNE Therapeutics

Several large investors have recently made changes to their positions in the company. Anson Funds Management LP purchased a new stake in VYNE Therapeutics during the 4th quarter valued at $739,000. Nantahala Capital Management LLC purchased a new position in shares of VYNE Therapeutics in the 4th quarter valued at $580,000. KVP Capital Advisors LP purchased a new position in VYNE Therapeutics in the fourth quarter worth $290,000. Shay Capital LLC acquired a new stake in VYNE Therapeutics in the third quarter worth about $165,000. Finally, Adage Capital Partners GP L.L.C. raised its holdings in shares of VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after buying an additional 300,000 shares during the last quarter. 83.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen upgraded VYNE Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, VYNE Therapeutics presently has an average rating of “Reduce”.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.